6,7-dihydroxyisoquinoline-3-carboxylic acids are potent inhibitors on the binding of insulin-like growth factor (IGF) to IGF-binding proteins: optimization of the 1-position benzoyl side chain.

doi:10.1016/S0960-894X(03)00321-4

Paper

6,7-dihydroxyisoquinoline-3-carboxylic acids are potent inhibitors on the binding of insulin-like growth factor (IGF) to IGF-binding proteins: optimization of the 1-position benzoyl side chain.

Published Jun 2, 2003 · Yun-fei Zhu, K. Wilcoxen, T. Gross

Bioorganic & medicinal chemistry letters

Q2 SJR score

12

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Optimizing the 1-position benzoyl side chain of 1-benzoyl isoquinolines can lead to potent inhibitors of insulin-like growth factor binding, with less labile catechol functionality.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

6,7-dihydroxyisoquinoline-3-carboxylic acids are potent inhibitors on the binding of insulin-like growth factor (IGF) to IGF-binding proteins: optimization of the 1-position benzoyl side chain.

Sign up to use Study Snapshot

References

Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins.

Isoquinoline analogues 1 and 2 show potential for developing oral therapeutics for IGF-responsive diseases by optimizing their binding to IGFBP-3 and releasing biologically active IGF-I.

Identification of a Nonpeptide Ligand That Releases Bioactive Insulin-like Growth Factor-I from Its Binding Protein Complex*

NBI-31772 is a promising nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex, potentially benefiting diabetes and other IGF-responsive diseases.

The somatomedin hypothesis: 2001.

The somatomedin hypothesis has been modified, with normal postnatal growth and development in mice possibly due to normal free IGF-I levels, rather than autocrine/paracrine IGF-I.

Insulin-like growth factors and their binding proteins: biological actions.

Insulin-like growth factors stimulate various biological processes, including DNA synthesis, proteoglycan synthesis, glycosaminoglycan synthesis, and protein synthesis, with their binding proteins playing a crucial role in their biological actions.

Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human.

IGFBP-5 is a novel insulin-like growth factor binding protein in rats and humans, with a high activity in kidney tissue and a short evolutionary history.

Citations